WALTHAM, Mass., Feb. 12, 2015 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced it will release its financial and operational results for the fourth quarter and full year ended December 31, 2014 on February 26, 2015 before the market opens. Histogenics will host a conference call on Thursday, February 26, 2015 at 8:00 a.m. EST to discuss the Company's financial and operational results for the fourth quarter and full year ended December 31, 2014, and other corporate activities. A question-and-answer session will follow Histogenics' remarks.
To participate on the live call, please dial (877) 930-8064 (domestic) or (253) 336-8040 (international) and provide the conference ID 83728349 five to ten minutes before the start of the call.
A live audio webcast of the presentation will be available via the "Investor Relations" page of the Histogenics website, www.histogenics.com. A replay of the webcast will be archived on Histogenics' website for approximately 60 days following the presentation.
About Histogenics Corporation
Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Histogenics' regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. Histogenics' first investigational product candidate, NeoCart®, leverages its platform to provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee.
CONTACT: Elissa Cote Tel: +1 (781) 547-7900 InvestorRelations@histogenics.com